{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-049317","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2022-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.894770+00:00","generated_at":"2026-06-26T05:04:34.452968+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Black Diamond Therapeutics discontinues BDTX-189, cuts workforce 30% to extend cash runway into Q3 2024","bullets":["Discontinued BDTX-189 due to rapid evolution of NSCLC treatment landscape (EGFR/HER2 Exon 20 insertions).","Reduced workforce by ~30% to increase operational efficiency and extend cash runway.","Cash runway extended into Q3 2024; $209M in cash, equivalents, and investments as of Dec 31, 2021.","Prioritized BDTX-1535 (Phase 1 for GBM/NSCLC) with clinical data update expected in 2023.","Prioritized BDTX-4933 (BRAF inhibitor); IND submission expected in first half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-049317","json":"https://secwatch.observer/filing/0001104659-22-049317.json","markdown":"https://secwatch.observer/filing/0001104659-22-049317.md","text":"https://secwatch.observer/filing/0001104659-22-049317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922049317/0001104659-22-049317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922049317/tm2213442d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:04:34.452968+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}